What is the recommended dosing for Tamiflu (oseltamivir) in the treatment of influenza?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tamiflu (Oseltamivir) Dosing Recommendations

For adults and adolescents ≥13 years, the standard treatment dose is 75 mg orally twice daily for 5 days, initiated within 48 hours of symptom onset. 1, 2

Adult and Adolescent Dosing (≥13 years)

Treatment:

  • 75 mg orally twice daily for 5 days 1, 3, 2
  • Must be initiated within 48 hours of symptom onset for maximum effectiveness 1, 3
  • Earlier initiation (within 12-24 hours) provides greater clinical benefit, reducing illness duration by an additional 53.9-74.6 hours compared to treatment started at 48 hours 4

Prophylaxis:

  • 75 mg orally once daily 1, 3
  • Post-exposure prophylaxis: 10 days following close contact with infected individual 1, 2
  • Seasonal prophylaxis: Up to 6 weeks during community outbreak 2
  • Immunocompromised patients: May continue up to 12 weeks 2

Pediatric Dosing (≥12 months)

Weight-based dosing for treatment (twice daily for 5 days): 1, 3, 2

  • ≤15 kg (≤33 lb): 30 mg twice daily
  • >15-23 kg (>33-51 lb): 45 mg twice daily
  • >23-40 kg (>51-88 lb): 60 mg twice daily
  • >40 kg (>88 lb): 75 mg twice daily

Prophylaxis dosing: Same weight-based doses but once daily for 10 days 1, 2

Infant Dosing (<12 months)

Term infants 0-8 months:

  • 3 mg/kg per dose twice daily for 5 days 1, 3

Infants 9-11 months:

  • 3.5 mg/kg per dose twice daily for 5 days 1, 3

Critical caveat: Prophylaxis is not recommended for infants <3 months unless the situation is judged critical due to limited safety data 1

Preterm Infant Dosing

Dosing based on postmenstrual age (gestational age + chronological age): 1, 3

  • <38 weeks postmenstrual age: 1.0 mg/kg twice daily
  • 38-40 weeks postmenstrual age: 1.5 mg/kg twice daily
  • >40 weeks postmenstrual age: 3.0 mg/kg twice daily

This age-based adjustment is essential to avoid toxicity due to immature renal function in preterm infants 1, 3

Renal Impairment Adjustments

For creatinine clearance 10-30 mL/min: 1, 3

  • Treatment: 75 mg once daily for 5 days (instead of twice daily)
  • Prophylaxis: 30 mg once daily for 10 days OR 75 mg every other day for 10 days (5 doses total)

Dose adjustment is critical in renal insufficiency to prevent drug accumulation 1

Formulation and Administration

Available formulations: 1, 2

  • Capsules: 30 mg, 45 mg, 75 mg
  • Oral suspension: 6 mg/mL when reconstituted

Oral suspension dosing volumes: 1

  • 30 mg dose = 5 mL
  • 45 mg dose = 7.5 mL
  • 60 mg dose = 10 mL
  • 75 mg dose = 12.5 mL

Administration tips:

  • Can be taken with or without food 1, 3, 2
  • Taking with food significantly improves gastrointestinal tolerability, reducing nausea and vomiting (which occur in approximately 10-15% of patients) 1, 4, 5
  • Capsules can be opened and contents mixed with liquid for patients unable to swallow capsules 1
  • If commercial suspension unavailable, pharmacies can compound suspension from capsules to achieve 6 mg/mL concentration 1

Important Clinical Pearls

Timing is critical: Treatment efficacy is highly dependent on early initiation—within 48 hours of symptom onset for treatment, and within 48 hours of exposure for post-exposure prophylaxis 1, 3, 4

Drug interaction: Avoid live attenuated influenza vaccine (LAIV) within 48 hours before oseltamivir use, and do not use oseltamivir for 14 days after LAIV vaccination 1

Common adverse effects: Gastrointestinal symptoms (nausea, vomiting, diarrhea) are the most common, typically mild and transient, resolving within 1-2 days 1, 4

References

Guideline

Oseltamivir Dosage and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Oseltamivir and Peramivir Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.